NEW YORK, April 01, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Target Corporation (NYSE: TGT) between August 26, 2022 and November 19, 2024, both dates inclusive (the “Class Period”), of the important April 1, 2025 lead plaintiff deadline.

NEW YORK, NY / ACCESS Newswire / April 1, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Target Corporation (NYSE:TGT) between August 26, 2022 and November 19, 2024, both dates inclusive (the "Class Period"), of the important April 1, 2025 lead plaintiff deadline. SO WHAT: If you purchased Target common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Vancouver, British Columbia--(Newsfile Corp. - March 31, 2025) - Bayhorse Silver Inc, (TSXV: BHS) (OTCQB: BHSIF) (FSE: 7KXN) (the "Company" or "Bayhorse") reports that final IP Survey results have been received for eastern side of the Bayhorse Silver Mine. Final IP data received shows five IP low-resistance targets.

The shift is particularly gloomy because Goldman for years has been one of the more optimistic houses when it comes to the outlook for growth—and it has been right.

BP is undervalued with a low P/E ratio, high yield, and bullish technical indicators, despite recent underperformance and mixed earnings results. BP's management plans a strategic reset, including potential M&A, and has increased dividends by 10%, signaling confidence despite macro challenges. Key risks include refining operation uncertainties, potential macroeconomic slowdown, and activist pressure, but April's seasonal trends are historically positive for BP.

NEW YORK, NY / ACCESS Newswire / March 30, 2025 / Rosen Law Firm PA WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Target Corporation (NYSE:TGT) between August 26, 2022 and November 19, 2024, both dates inclusive (the "Class Period"), of the important April 1, 2025 lead plaintiff deadline. SO WHAT: If you purchased Target common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Preliminary data from Cohort 4 of the ENSURE study supports a novel enrichment strategy to utilize BRII-179 to identify patients who are immune responders and have the potential to achieve higher HBsAg loss at EOT 48-week EOT data from Cohort 1-3 of the ENSURE study clearly suggests the added benefits of elebsiran towards achieving a higher rate of HBsAg loss in combination with PEG-IFNα DURHAM, N.C. and BEIJING, China , March 30, 2025 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio," or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet medical needs, announced new data from its ongoing Phase 2 ENSURE study as a late-breaking oral presentation at the 34th Annual Meeting of Asian Pacific Association for the Study of the Liver (APASL 2025) in Beijing, China.

NEW YORK, NY / ACCESS Newswire / March 30, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Target Corporation ("Target" or "the Company") (NYSE:TGT) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Target securities between March 9, 2022 and November 19, 2024, both dates inclusive (the "Class Period").

NEW YORK, NY / ACCESS Newswire / March 29, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Target Corporation (NYSE:TGT) between August 26, 2022 and November 19, 2024, both dates inclusive (the "Class Period"), of the important April 1, 2025 lead plaintiff deadline. SO WHAT: If you purchased Target common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Travelers (TRV) remains a buy due to strong quarterly results, resilient performance, and favorable valuation despite recent market pressures and extreme weather events. TRV's Q4 non-GAAP EPS of $9.15 beat forecasts by $2.54, with revenue up 20% YoY, driven by strong homeowners insurance margins. Key risks include the financial impact of LA wildfires, macro uncertainties, and insurance inflation, but TRV's pricing power and technical chart are encouraging.